Last reviewed · How we verify
Fecal microbiome
At a glance
| Generic name | Fecal microbiome |
|---|---|
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MIMICC Study in Patients With Colorectal Cancer (NA)
- Sample Collection From Healthy Volunteers for Assay Optimization
- Impact of the Early Life Virome Development on Bronchopulmonary Dysplasia in Preterm Neonates
- Oral Aromatase Inhibitors Modify the Gut Microbiome
- Polyphenol Metabotypes in People With Diabetes Type 2
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer (EARLY_PHASE1)
- Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fecal microbiome CI brief — competitive landscape report
- Fecal microbiome updates RSS · CI watch RSS
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico portfolio CI